Supreme Court Declines to Review Purdue Pharma’s OxyContin Patent Dispute
The U.S. Supreme Court refuses to hear Purdue Pharma’s appeal challenging patent rulings related to OxyContin, leaving lower court decisions intact.
The U.S. Supreme Court has opted not to take up Purdue Pharma’s appeal concerning patent litigation over its opioid medication OxyContin. This decision means that prior rulings against Purdue in the patent dispute remain in effect, potentially impacting the company’s control over the drug’s intellectual property right…